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Abstract: 
Clostridium difficile infection (CDI) is a leading cause of infectious diarrhea in solid organ 
transplant recipients (SOT). We aimed to assess incidence, risk factors and outcome of CDI 
within the Swiss Transplant Cohort Study (STCS). We performed a case-control study of 
SOT recipients in the STCS diagnosed with CDI between May 2008 and August 2013. We 
matched two control subjects per case by age at transplantation, sex and transplanted organ. 
A multivariable analysis was performed using conditional logistic regression to identify risk 
factors and evaluate outcome of CDI. Two thousand one hundred and fifty-eight SOT 
recipients, comprising 87 cases of CDI and 174 matched controls were included. The overall 
CDI rate per 10’000 patient days was 0.47 (95% confidence interval (CI): [0.38, 0.58]), with 
the highest rate in lung (1.48, 95% CI: [0.93, 2.24]). In multivariable analysis, proven 
infections (hazard ratio (HR) 2.82, 95% CI: [1.29, 6.19]) and antibiotic treatments (HR=4.51, 
95% CI: [2.03, 10.0]) during the preceding three months were independently associated with 
the development of CDI. Despite mild clinical presentations, recipients acquiring CDI post-
transplantation had an increased risk of graft loss (HR=2.24, 95% CI: [1.15, 4.37], p=0.02). 
These findings may help to improve the management of SOT recipients. 
 
Introduction 
Clostridium difficile is a leading cause of infectious diarrhea with a reported incidence rate of 
7 cases per 10’000 patient-bed days in Europe (1). Solid organ transplant (SOT) recipients 
are at higher risk for CDI than the general population, due to numerous risk factors including 
severe underlying diseases, immunosuppression, recent surgery, antibiotic treatment, 
ganciclovir prophylaxis, gastric acid suppression and prolonged hospital stay (2-5). A 
recently published meta-analysis in SOT recipients reported an overall prevalence of 7.4% 
(6). The clinical spectrum of CDI ranges from asymptomatic colonization to fulminant 
pseudomembranous colitis. Knowledge about the severity of CDI and the impact on graft 
function in SOT is scarce and contradictory; while some authors have described a worse 
outcome of CDI in SOT recipients (2, 4, 5, 7, 8), a recent Spanish cohort study and two US 
studies reported a good prognosis of CDI in SOT recipients (9-11). These aspects are 
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important, as newer treatment guidelines for CDI stratify according to the clinical severity of 
disease emphasizing the reduction of recurrence of CDI (12, 13). Indeed, whereas both oral 
metronidazole and vancomycin were equally effective for treatment of mild CDI, response 
rates were superior for vancomycin in patients with severe CDI in a randomized trial (14). 
Accordingly, the recently updated guidelines of the European Society for Clinical 
Microbiology and Infectious Diseases (ESCMID) and the latest US-American guidelines 
recommend as first option oral metronidazole for patients with non-severe and oral 
vancomycin for severe CDI (12, 13). Fidaxomicin achieved significantly lower rates of 
recurrence of CDI in two clinical trials (15, 16). Accordingly, the ESCMID guidelines 
recommend the use of fidaxomicin for patient at risk for recurrent CDI (13). 
Our main objective was to determine the outcome of CDI in SOT recipients. Secondary aims 
were to describe incidence and clinical severity, and to identify risk factors for CDI within this 
population. 
 
Methods  
Patients and study design  
The Swiss Transplant Cohort Study (STCS) is an observational national cohort, enrolling all 
SOT recipients followed at six Swiss university centers. Details on data definitions and the 
cohort structure have been previously published (17, 18). For the present study, all SOT 
recipients prospectively enrolled in the STCS between May 2008 and August 2013 with 
written informed consent were included. The protocol was approved by the ethics committee 
of all participating centers. Patient’s data were collected in the STCS database at enrollment, 
6 and 12 months, and yearly after transplantation on standardized electronic case report 
forms (eCRF). Clinical data extracted from the STCS database included demographic data, 
infections, antibiotic and antiviral prophylaxis, induction and maintenance 
immunosuppressive treatments, as well as medical co-morbidities and surgical 
complications. To analyze risk factors that are not routinely registered in the STCS database 
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we performed a nested case-control study, applying an incidence density sampling matching 
two controls to each case by age at transplantation (differences ≤ 10 years), sex and type of 
transplant. Controls were defined as SOT recipients without captured CDI in the SCTS 
database. The non-occurrence of CDI in these recipients was double checked in the hospital 
charts and local laboratory databases. For all cases and controls we extracted additional 
data including type of anti-infective treatment in the three months preceding CDI (19), intake 
of a proton-pump inhibitor (PPI), as well as hospital and intensive care unit (ICU) stay from 
the local laboratory databases and hospital charts, and captured them in dedicated eCRF. 
For cases, we additionally collected the clinical severity of CDI classified in three categories 
(definition see below), hospital and ICU admission due to CDI, peak white blood count, 
platelet nadir, rise in serum creatinine and the antibiotic treatment for CDI. There were no 
clinical variables with missing data included in the multivariable analyses.  
 
 
 
Definitions  
To assure homogeneous assessment of the infectious disease events in the STCS, 
specifically trained infectious diseases specialists at each center record the occurrence of 
infectious events using standardized definitions (17). Proven CDI was defined according to 
the criteria of the STCS Infectious Diseases Working Group as follows: presence of 
symptoms (diarrhea) and/or clinical signs (evidence of pathologic findings in endoscopy or 
radiology) together with pathogen isolation (by culture, or antigen) and Clostridium difficile-
toxin detection. CDI clinical severity was graded (mild-to-moderate / severe disease / severe 
and complicated disease) as proposed by the American College of Gastroenterology in 2013, 
without considering the serum albumin level, since this value was available only for a 
minority of patients (12). Mild-to-moderate disease was defined as diarrhea with any 
additional signs or symptoms not meeting criteria of severe or complicated diarrhea. Severe 
disease included abdominal tenderness or leucocytosis > 15’000 cells/mm3. Severe and 
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complicated disease required one or more of the following criteria: ICU admission for CDI, 
hypotension, fever > 38.5°, paralytic ileus or significant abdominal distension, mental status 
changes, leucocytosis > 35 G/l or leucopenia < 2 G/l, serum lactate levels >2.2mmol/l, and 
end organ failure. Clinical recurrence was defined as reappearance of diarrhea after the 
cessation of therapy, isolation of C. difficile or its toxin in stool, and need for retreatment. No 
distinction between relapse and reinfection was possible, since the C. difficile strains were 
not available for further analysis. Infections in the three months before CDI were defined 
according to the criteria of the STCS Infectious Diseases Working Group. A proven bacterial 
infection required a pathogen isolated together with clinical signs and/or symptoms and 
treatment given. A proven viral disease required detection of virus replication with 
corresponding pathology in biopsy tissues. A viral syndrome consisted of detection of virus 
replication and non-organ-specific clinical symptoms. For fungal infections, we used the 
EORTC/MSG Consensus Group definitions (20). We defined graft loss as follows: recurrence 
of insulin-dependence following pancreas transplant, dialysis post-renal transplant, re-
transplantation post-heart, liver or lung transplant. All-cause mortality, and mortality assumed 
to be related to CDI were collected separately. 
 
Statistical analysis  
Patients’ baseline characteristics are shown descriptively, separated for patients with and 
without CDI. CDI-specific information for patients with at least one CDI episode, follow-up 
and outcome information are also presented. Cumulative incidence rates for the first CDI 
episode were calculated by transplant type, treating death before CDI as competing risk. 
Based on the case-control study, risk factors for CDI post-SOT were investigated in 
univariate and multivariable conditional logistics regression models. We determined risk 
exposure either at time of transplantation, or when adequate three months prior to first CDI 
occurrence within the case-control study. Due to the large number of potential risk factors 
and the relatively low number of CDI events, we used the conservative Bonferroni method to 
adjust for the multiple testing problem. The final multivariable model, restrained to generic 
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terms, was based both on the univariate analysis and on clinical relevance of potential risk 
factors, excluding hospitalization because of an excessively large confident interval. We also 
investigated the probability for recurrent CDI episodes using logistic regression models 
without further risk adjustment. 
We further performed Cox proportional hazard (PH) models to evaluate the effect of CDI on 
the occurrence of graft loss and death. We applied non-informative censoring about the 
outcome (death, graft loss). CDI was considered as time-dependent risk factor in time-to-
event analyses. In addition to CDI, we included baseline and time-dependent risk factors 
(surgical complications, medical problems, rejection, and relevant infections) in the graft loss 
analysis (Table 5). The PH assumption was verified by plotting Schoenfeld residuals to 
visualize the effect over time. When the PH assumption was violated, but the effect strong 
and without change of the direction, no restrictions were included and the interpretation not 
hampered. All statistical analyses were performed using the statistical software R (version 
3.2.0; R Foundation for Statistical Computing, Vienna, Austria). 
 
Results: 
Population characteristics and incidence of CDI 
During the observation period, 2400 SOTs were performed in Switzerland. After exclusion of 
combined transplants and patients who did not sign the informed consent, we included 2158 
patients (1261 kidney, 454 liver, 224 lung, 164 heart and 55 kidney-pancreas recipients) in 
the present study. Within the study population, we identified 87 patients (cases) with 102 
proven CDI episodes corresponding to a crude incidence of 4.0%. CDI was observed in 35 
kidney, 23 liver, 22 lung and 7 heart recipients (Table 1). The cumulative incidence rate for 
the first CDI episode per patient at one year post SOT was 0.09 for lung, 0.05 for liver, 0.04 
for heart and 0.02 for kidney recipients (Figure 1). The overall CDI rate was 0.47 (95%CI: 
[0.38-0.58]) per 10’000 patient-days. Lung recipients had the highest (1.48, [0.93-2.24]) and 
kidney recipients the lowest rate (0.30, [0.21-0.41]). Almost all CDI events occurred in the 
first year following transplantation. The median time-lag from transplant to CDI was 70 days 
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(interquartile range (IQR): [21-189]). Lung recipients had the shortest time-lag (31 days, IQR: 
[7-129]), whereas kidneys had the longest (115 days, IQR: [38-308]). Acquisition of CDI was 
nosocomial in 49 (56%) patients. CDI diagnosis in the 102 CDI episodes was based on 
culture and toxin detection (N=60), antigen and toxin detection (N=24) and exclusively 
Clostridium difficile-toxin detection by PCR (N=18).  
 
Risk factors for CDI development 
In univariate analysis, infections, especially proven bacterial infections, anti-infective therapy, 
antibiotic therapy, all ß-lactams and quinolones, and hospitalization in the three months 
preceding the event were associated with the development of CDI (Table 2). In the 
multivariable analysis, infections (odds ratio (OR) 2.82, 95% CI: [1.29, 6.19], p=0.01) and 
intake of antibiotic treatments (OR=4.51, 95% CI: [2.03, 10.00], p<0.001) during the three 
months preceding the event remained significantly associated with CDI development. 
 
Treatments  
Seventy-one (83.5%) cases were treated with metronidazole for a median duration of 11 
days (IQR: [10, 15]), 10 (11.8%) cases were treated with oral vancomycin for a median 
duration of 11 days (IQR: [10, 13]) and 4 (4.7%) cases received a combined treatment with 
metronidazole and vancomycin (Table 3). Two cases with a mild course of CDI recovered 
spontaneously without any treatment. Recurrent CDI was treated by metronidazole in 9, 
vancomycin in 2 cases, and combination therapy in 3 cases.  
 
Clinical severity and recurrence 
Sixty-five of 87 cases (74.7 %) had a mild to moderate, 19 (21.8%) a severe, and 3 (3.4%) a 
severe complicated course of CDI (Table 3). Seventeen (19.5%) patients required hospital 
admission and one patient ICU admission for treatment of the CDI. The median white blood 
cell count at the time of diagnosis was 8.9 G/L (IQR: [5.5, 11.3]), with 43 (51%) patients 
having a value outside the normal range of 4-10 G/l. Four-teen (16.1%) patients experienced 
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more than a single CDI event, 13 patients had 2 events and one patient 3 events. The 
median time between the first and the second event was 56 days (min=14, max=1127). 10 of 
14 recurrent CDI occurred within 8 weeks after the first episode. In univariate logistic 
regression, we found no significant differences in age, gender, transplant type, clinical 
severity and treatment for 1st CDI between patients with single and recurrent CDI episodes.  
(Table 3). 
 
Outcome analysis 
Two hundred three out of 2158 SOT recipients died, including 14 out of 87 CDI cases (9.1% 
versus 16.1%, Tables 1 and 4). No death was directly linked to CDI. Two deaths occurred 
within three months following CDI. In univariate analysis, patients who died were older (56 
versus 49 years, p<0.001) and patients transplanted for heart, liver and lung had a higher 
risk to die compared to kidney recipients (p<0.001) (Table 6). This was confirmed in 
multivariable analysis. CDI increased mortality in univariate analysis (HR= 2.31; 95% CI: 
[1.33, 3.99], p=0.003), however this effect was no longer significant in the multivariable 
model (HR=1.63, 95% CI: [0.94, 2.83], p=0.085) (Table 6). 
In univariate analysis for graft loss, baseline recipient characteristics (age, gender, 
transplant) showed no significant effects (p>0.05) (Table 6). In contrast, the occurrence of 
CDI was associated with graft loss (HR=3.72, 95% CI: [1.92, 7.20], p<0.001). To confirm this 
effect, we accounted for further time-dependent risk factors potentially associated with graft 
loss. These included general and transplant specific surgical complications, medical 
problems, rejection, and both systemic and transplant specific infections (Table 5). Combined 
surgical complications, medical problems, relevant infections, as well as both bacterial and 
fungal infections analyzed alone or in combination were all significantly associated with graft 
loss in univariate analyses (Table 6). In contrast, viral infections, including or not CMV, did 
not increase the risk of graft loss. In a multivariable model, surgical complications (HR=7.22, 
95% CI: [4.53, 11.50], p<0.001), medical problems (HR=2.35, 95% CI: [1.33, 4.15], p=0.003), 
rejection (HR=7.56, 95% CI: [4.70, 12.18], p<0.001), bacterial and fungal infections 
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(HR=3.67, 95% CI: [2.22, 6.06], p<0.001), as well as CDI (HR=2.24, 95% CI: [1.15, 4.37], 
p=0.02) remained independent risk factors for graft loss (Table 6).  
 
 
 
Discussion 
We report the results of a nationwide study of 87 cases of Clostridium difficile infections 
among 2158 SOT recipients in the STCS. We identified and confirmed preceding infection 
and antibiotic use as risk factors for CDI. We showed that despite most episodes being 
clinically benign, CDI was associated with a 2.2-fold increased risk of graft loss. 
The crude incidence of CDI in our prospectively evaluated cohort including >90% of all Swiss 
SOT recipients was 4% corresponding to an infection rate of 0.47 per 10 000 patient-days. 
This incidence is low as compared to previous reports, including a meta-analysis comprising 
30 studies reporting an overall incidence of 7.4% CDI in SOT recipients (6). Methodological 
differences in calculating the occurrence of CDI in SOT might explain such differences. Of 
note the incidence of CDI in the general Swiss population in hospitals compares to other 
European countries (4.8 cases vs 4.1 cases per 10’000 patients-days, respectively) (21). In 
accordance with earlier reports, lung recipients had the highest incidence rate as well as the 
earliest occurrence after transplantation (4, 5, 9, 22). Consequently, some authors have 
suggested to implement metronidazole as prophylaxis early after lung transplantation (23).  
Of major importance is our observation that despite low clinical severity and good therapeutic 
response, CDI in SOT recipients was associated with an increased risk of graft loss. An 
impact on graft function has been previously suggested for non-infectious diarrhea (24), but 
to our knowledge was never associated with CDI. The therapeutic efficacy of fecal 
transplantation in the treatment of CDI highlights the importance of CDI as a marker of 
intestinal dysbiosis (25, 26). It is likely, that whereas the immune dysregulation is the initial 
insult leading to intestinal dysbiosis in SOT recipients, potentially further worsened by 
antibiotic treatments (27), CDI aggravates this intestinal microbial imbalance. Inflammation 
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associated with CDI could also provoke graft rejection via innate immune mechanisms. In 
such a scenario, dysbiosis or the C. difficile itself could enhance TH-responses affecting the 
graft. However, whether CDI itself or this exacerbated intestinal dysbiosis increases the risk 
of graft loss is impossible to distinguish at this point. Diarrhea and intestinal dysbiosis could 
both interfere with adequate absorption and/or the metabolism of immunosuppressive 
agents, thereby increasing the risk for graft failure. The higher rates of graft loss and death in 
CDI cases could also be an indirect marker of sicker patients and an unfavorable post-
transplantation course, as evidenced by the higher numbers of infections and antibiotic 
administration in cases compared to controls in this study, rather than a direct effect of the 
CDI. In line with this hypothesis is the recent report describing a higher number of organ 
specific complications among SOT recipients (28). Further prospective studies, analyzing 
CDI and microbiome changes, as well as immune responses will be needed to deceiver the 
type of association between CDI and graft loss, and its underlying mechanisms.  
All infectious disease events are systematically collected in the STCS. This allowed us to 
identify previous bacterial, but not viral and fungal, infections that occurred during the 
preceding three months as major risk factors for CDI development. Clearly, we confirm 
antibiotic treatments, including carbapenems, cephalosporins, quinolones and penicillins, as 
a significant risk factor (OR≥4) in SOT recipients for developing CDI. Still, as previously 
noted, 25% of patients with CDI had not received antibiotics in the last 3 months (27). In 
these cases, the development of CDI has been suggested to be linked to immune 
dysfunction in SOT recipients (27). As in the Spanish cohort, we found no association with 
induction therapy or with different immunosuppression regimens (9). 
In our study, 75% of CDI episodes were mild to moderate, 3 cases (3.4%) had a severe 
complicated course, and no patient required a surgical intervention or died due to CDI. This 
is a more benign course as compared to previously published data reporting 5.3% 
complicated cases (6). The severity of CDI has been shown to depend on the presence of 
circulating hyper-virulent strains such as ribotype 027 (29). It is likely that the favorable 
outcome in the present report may be linked to a low prevalence of hyper-virulent ribotypes 
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in Switzerland (30). In correlation with the low clinical severity, most of our cases (83.5%) 
were treated with metronidazole for a medium duration of 11 days according to current 
guidelines (27). CDI recurred in 16.1 % cases, less frequently as compared to 19.7% 
reported in the literature (6). In the absence of genotyping differentiation between relapses 
and reinfections was not possible. However, 59% of the recurrent CDI episodes occurred 
within 8 weeks after the first suggesting these second events to be relapses rather than 
reinfections.  
Our study has some limitations. The CDI incidence rate may be underestimated, especially 
for CDI episodes that could have occurred outside the transplant centers. However, most 
CDIs occurred early after transplant when SOT recipients were in close contact with the 
transplant center and we suppose that only very few events have been missed. The use of 
different diagnostic tests, including culture, detection of antigens and Clostridium difficile-
toxin, by enzyme immune assay and PCR might also have affected incidence rates. Despite 
our study being one of the largest series of CDI in SOT recipients published to date (6), the 
number of CDI per transplant remained small and required pooling of specific risk factors in 
the multivariable analysis.  
The strength of our study remains the comprehensive nationwide enrolment of all Swiss SOT 
recipients, which guaranties highly representative data of the real-life situation in Switzerland. 
In conclusion, preceding bacterial infections and antibiotic treatment were risk factors for the 
development of CDI after SOT. Despite mild clinical presentation, and good clinical 
responses, SOT recipients with CDI were at increased risk for graft loss. These data support 
the importance of restrictive antibiotic use in the prevention of CDI and underlines the need 
for close surveillance of graft function in SOT recipients developing CDI. Further studies are 
needed to assess the impact of CDI on allograft function.   
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Figure legends: 
 
Figure 1. Cumulative incidences of first CDI episodes according to transplant.  
Shown are the two-year cumulative incidences of first episodes of C. difficile infections in 87 
SOT recipients with CDI according to allograft type. 
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Tables:  
Table 1. Characteristics of 2158 SOT recipients according to CDI  
 
 
 Recipients with CDI 
 
Recipients without CDI 
 
Number of SOT recipients, N (%) 87 (4.0) 2071 (96.0) 
Age at transplantation, mean (SD) 52.9 (14.6) 49.6 (16.1) 
Male, N (%) 50 (57.5) 1329 (64.2) 
Type of transplantation, N (%)    
    Kidney  35 (40.2) 1226 (59.2) 
        Living donation 8 (22.9) 525 (42.8) 
    Liver  23 (26.4) 431 (20.8) 
        Living donation 2 (8.7) 26 (6) 
    Lung 22 (25.3) 202 (9.8) 
    Heart 7 (8.0) 157 (7.6) 
    Kidney – Pancreas 0 (0.0) 55 (2.7) 
Diabetes mellitus, N (%) 20 (23) 347 (16.5) 
Follow-up time (yrs), median [IQR] 3.3 [1.9, 4] 2.3 [1.1, 3.8] 
Graft loss, N (%) 
    before CDI 
    after CDI 
14 (16.1) 
4 (4.6) 
10 (11.5) 
117 (5.6) 
 
 
Death, N (%) 14 (16.1) 189 (9.1) 
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 Table 2: Risk factors for CDI 
 
Risk exposure at or within three months 
prior to CDI  
Cases 
(n=87) 
Controls 
(n=174) 
Univariate 
OR [95%CI] 
adj. p-value 
Multivariable 
OR [95%CI] 
adj. p-value 
Infections, N (%) 
[Mean number per patient*, (min, max)] 
46 (52.9) 
[1.72, (1,8)] 
35 (20.1) 
[1.31,(1,4)] 
5.10 [2.70, 9.63] 
<0.001 
2.82 [1.29, 6.19] 
0.01 
- Proven bacterial infections 36 (41.4) 26 (14.9) 
4.25 [2.21, 8.16] 
<0.001 
 
- Proven viral infections & viral syndromes 13 (14.9) 8 (4.6) 
3.09 [1.27, 7.49] 
0.379 
 
- Proven or probable fungal infections 7 (8.0) 4 (2.3) 
3.50 [1.03, 11.96] 
1 
 
Anti-infective prophylaxis, N (%) 68 (78.2) 130 (74.7) 
1.37 [0.63, 2.99] 
1 
0.96 [0.36, 2.57] 
0.936 
Anti-infective therapy, N (%) 69 (79.3) 70 (40.2) 
7.96 [3.72,17.02] 
<0.001 
 
Antibiotics, N (%) 65 (74.7) 61 (35.1) 
7.41 [3.60, 15.26] 
<0.001 
4.51 [2.03, 10.00] 
<0.001 
- Penicillins, N (%) 
  [duration (days), median (IQR)] 
42 (48.3) 
[9, (7,14)] 
33 (19) 
[9, (6,14)] 
4.34 [2.28, 8.28] 
<0.001 
 
- Cephalosporins, N (%)  
19 (21.8) 
[7, (5,10)] 
11 (6.3) 
[10, (5,16)] 
4.47 [1.84, 10.86] 
0.028 
 
- Carbapenems, N (%) 
27 (31.0) 
[9, (6,14)] 
21 (12.1) 
[9, (9,14)] 
5.80 [2.33, 14.45] 
0.005 
 
- Quinolones, N (%) 
24 (27.6) 
[13, (6,19)] 
14 (8.0) 
[10, (6,13)] 
4.00 [1.95, 8.22] 
0.005 
 
- Glycopeptides, N (%) 
10 (11.5) 
[15, (7,29)] 
15 (8.6) 
[9, (6,15)] 
1.26 [0.50, 3.19] 
1 
 
- Other antibiotics, N (%) 
19 (21.8) 
[9, (6,29)] 
15 (8.6) 
[9, (4,21)] 
2.85 [1.37, 5.92] 
0.153 
 
Antiviral therapy, N (%) 24 (27.6) 21 (12.1) 
3.08 [1.51, 6.29] 
0.061 
1.55 [0.65, 3.70] 
0.32 
Antifungal therapy, N (%) 14 (16.1) 10 (5.7) 
2.97 [1.28, 6.89] 
0.341 
1.12 [0.40, 3.10] 
0.829 
Proton pump inhibitor (PPI), N (%) 84 (96.6) 155 (89.1) 
3.63 [1.02, 12.92] 
1 
1.25 [0.24, 6.43] 
0.788 
Hospitalization, N (%) 85 (97.7) 125 (71.9) 
41.18 [5.56,305.10] 
0.008 
 
ICU stay, N (%) 58 (66.7) 91 (52.3) 
3.61 [1.57, 8.31] 
0.077 
2.34 [0.83, 6.61] 
0.108 
Induction therapy, N (%) 59 (67.8) 116 (66.7) 
1.06 [0.59, 1.90] 
1 
0.75 [0.32, 1.72] 
0.491 
Immunosuppression at time of CDI     
- Corticosteroid, N (%) 76 (87.4) 146 (83.9) 
1.39 [0.62, 3.14] 
1 
 
- Calcineurin inhibitors, N (%) 82 (94.3) 154 (88.5) 
2.23 [0.79, 6.33] 
1 
 
- Antimetabolites, N (%) 80 (92.0) 152 (87.4) 
1.67 [0.69, 4.14] 
1 
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- mTOR-inhibitors, N(%) 8 (9.2) 8 (4.6) 
2.11 [0.76, 5.89] 
1 
2.30 [0.63, 8.40] 
0.206 
 
* Mean number of infections in patients with at least one infection. 
 
 
 
Table 3. Clinical variables and course of patients with single and multiple CDI events 
 
 Single CDI Multiple CDI Total p-value* 
Total N 73 14 87  
Male, N (%) 39 (53.4) 11 (78.6) 50 (57.5) 0.09 
Age at transplant, mean (SD) 52.3 (14.7) 56.1 (13.8) 52.9 (14.6) 0.37 
Transplanted organ, N (%)    0.88 
    Heart 7 (9.6) 0 (0) 7 (8.0)  
    Kidney 30 (41.1) 5 (35.7) 35 (40.2)  
    Liver 19 (26.0) 4 (28.6) 23 (26.4)  
    Lung 17 (23.3) 5 (35.7) 22 (25.3)  
Clinical course, N (%)    0.76 
    Mild – moderate 55 (75.3) 10 (71.4) 65 (74.7)  
    Severe 16 (21.9) 3 (21.4) 19 (21.8)  
    Severe with complication 2 (2.7) 1 (7.1) 3 (3.4)  
WBC (G/l) at 1st CDI, median [IQR] 8.9 [5.8, 10.8] 7.3 [4.2, 19.9] 8.9 [5.5, 11.3] 0.88 
     
 out of range 4-10 G/l, N (%) 34 (46.6) 9 (64.3) 43 (49.4)  
Treatment of 1st CDI, N (%) 71 (97.3) 14 (100) 85 (97.7) 0.99 
    Metronidazole 62 (87.3) 9 (64.3) 71 (83.5)  
    Vancomycin 8 (11.0) 2 (14.3) 10 (11.8)  
    Metronidazole and Vancomycin  1 (1.4) 3 (21.4) 4 (4.7)  
 
IQR, interquartile range; SD, standard deviation 
* p-values from unadjusted logistic models for probability of 2
nd
 CDI event 
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Table 4. Characteristics of 2158 SOT recipients for outcome analysis 
 
 Recipients with graft loss 
 
Recipients without graft loss 
 
Number of SOT recipients, N (%) 131 (6.1) 2027 (93.9) 
Baseline characteristics 
Age at transplantation, mean (SD) 51.5 (14.8) 49.7 (16.1) 
Male, N (%) 85 (63.9) 1294 (63.8) 
Type of transplantation, N (%)    
    Kidney (incl. Kidney-Pancreas) 80 (61.1%) 1236 (61%) 
    Liver  26 (19.8%) 428 (21.1%) 
    Lung 13 (9.9%) 211 (10.4%) 
    Heart 12 (9.2%) 152 (7.5%) 
Diabetes mellitus at TX, N (%) 26 (19.8%) 341 (16.8%) 
Hypertension at TX, N (%) 72 (55%) 1187 (58.6%) 
Time-dependent characteristics (until death, graft loss or censoring) 
CDI in FUP, N (%) 10 (7.6%) 73 (3.6%) 
Surgical complications in FUP, N (%) 29 (22.1%) 127 (6.3%) 
Medical problems in FUP, N (%) 16 (12.2%) 231 (11.4%) 
Rejections in FUP, N (%) 64 (48.9%) 715 (35.3%) 
Bacterial/Fungal ID in FUP, N (%) 46 (35.1%) 593 (29.3%) 
 
 Alive 
 
Deaths 
 
Number of SOT recipients, N (%) 1955 (90.6%) 203 (9.4%) 
Baseline characteristics 
Age at transplantation, mean (SD) 49.11 (16.25) 56.1 (12.37) 
Male, N (%) 1245 (63.7%) 134 (66%) 
Type of transplantation, N (%)    
    Kidney (incl. Kidney-Pancreas) 1248 (63.8%) 68 (33.5%) 
    Liver  395 (20.2%) 59 (29.1%) 
    Lung 176 (9%) 48 (23.6%) 
    Heart 136 (7%) 28 (13.8%) 
Time-dependent characteristics (until death or censoring) 
CDI in FUP, N (%) 73 (3.7%) 14 (6.9%) 
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Table 5: Definitions and description of time-dependent risk factors 
 
Risk factor Definition / Composition Duration 
CDI 
Clinical symptoms (diarrhea)  
+ Clinical signs (pathologic findings by endoscopy or radiology) 
+ Pathogen isolation (culture, or antigen) and C. difficile-toxin 
Permanent exposure after 
occurrence 
Surgical 
complications 
- Transplant specific vascular complications: 
   - Liver: arterial or portal vein thrombosis/leak 
   - Lung: bronchial arterial or venous thrombosis/leak 
   - Heart: acute ischemia or coronary heart disease 
   - Kidney: renal artery or venous thrombosis/leak 
 
- Transplant specific anastomotic complications: 
  - Liver: biliary stenosis/leak¨ 
  - Lung: bronchial stenosis/dehiscence 
  - Kidney: ureter stenosis/leak 
 
- Biopsy related complications 
- Hemorrhagic complications 
Exposure for 6 months after 
occurrence 
Medical 
problems* 
- Tumor in transplant (liver/lung) 
- Arrhythmia or valvulopathy (heart)  
- Renal failure (not kidney)  
- Recurrence of initial disease leading to transplant 
- Arrhythmia/valvulopathy:  
exposure for 1 month 
after occurrence 
- Tumor, recurrence of initial 
disease, renal  
failure: permanent 
exposure after occurrence 
Rejection Biopsy proven and treated rejections  
Exposure for 1 month after 
occurrence 
Infections 
- Bacterial infections: 
- proven infections in the transplant 
- bacteremia 
 
- Fungal infections: 
- fungemia 
- all transplants: probable/proven infections due to 
  Aspergillus spp./Zygomycetes spp.  
- Liver: Candida spp. 
- Lung: Pneumocystis 
  
- Proven viral infections in the transplant: 
 - Liver: hepatitis B/ C viruses 
 - Lung: respiratory viruses
+
 
 - Kidney: BK polyomavirus 
 
- Probable/proven CMV disease/CMV syndrome 
- Aspergillus, Zygomycetes 
hepatitis B and C, BKV and 
CMV: permanent exposure after 
occurrence 
 
- All other infections:   
exposure for 1 month  
after occurrence 
 
+ 
Respiratory viruses: Adenovirus, Influenza, Parainfluenza, Metapneumovirus, Rhinovirus and RSV 
* Diabetes and hypertension were analyzed individually 
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Table 6. Risk of death and graft loss of SOT recipients with CDI 
 
 
 
 
Mortality analysis Graft loss analysis 
 
Univariate 
HR [95% CI] 
p-value 
Multivariable 
HR [95% CI] 
p-value 
Univariate 
HR [95% CI] 
p-value 
Multivariable 
HR [95% CI] 
p-value 
Baseline characteristics 
Recipient’s age at SOT 
(years) 
1.03 [1.02, 1.05] 
<0.001 
1.04 [1.03, 1.05]  
<0.001 
1.01 [1.00, 1.02] 
0.16 
 
Male vs. Female 
1.09 [0.82, 1.46] 
0.55 
 
1.04 [0.73, 1.49] 
0.83 
 
Type of transplant 
- [-]  
<0.001° 
- [-]  
<0.001° 
- [-]  
0.83° 
 
- heart vs kidney 
3.90 [2.51, 6.06]       
<0.001 
4.36 [2.81, 6.79] 
 <0.001 
1.33 [0.72, 2.44] 
0.36 
 
- liver vs kidney 
2.77 [1.95, 3.92]       
<0.001 
2.81 [1.98, 3.99]  
<0.001 
0.99 [0.64, 1.54] 
0.97 
 
- lung vs kidney 
4.77 [3.29, 6.90]       
<0.001 
4.96 [3.41, 7.20] 
<0.001 
1.02 [0.57, 1.84] 
0.94 
 
Diabetes 
1.22 [0.80, 1.88] 
0.354 
   
Hypertension 
0.82 [0.58, 1.16] 
0.258 
   
Time-dependent risk factors
§ 
Clostridium infection 
(CDI) 
2.31 [1.33, 3.99] 
0.003 
1.63 [0.94, 2.83] 
0.085 
3.72 [1.92, 7.20] 
<0.001 
2.24 [1.15, 4.37] 
0.02 
Surgical complications   
11.99 [7.71, 18.64] 
<0.001 
7.22 [4.53, 11.50] 
<0.001 
Medical problems   
3.54 [2.01, 6.23] 
<0.001 
2.35 [1.33, 4.15] 
0.003 
Rejection   
10.58 [6.67, 16.77] 
<0.001 
7.56 [4.70, 12.18] 
<0.001 
Relevant infections   
3.01 [1.92, 4.71] 
<0.001 
 
- bacterial / fungal   
4.90 [3.01, 8.00] 
<0.001 
3.67 [2.22, 6.06] 
<0.001 
 
      bacterial only   
2.32 [1.12, 4.81] 
0.02 
 
     bacteremia only   
8.22 [4.53, 14.92] 
<0.001 
 
- fungal only   
7.05 [2.23, 22.33] 
<0.001 
 
     fungemia only   
7.19 [1.00, 51.89] 
0.05 
 
- viral (incl. CMV)   
1.58 [0.73, 3.44] 
0.25 
 
     viral only   
0.75 [0.10, 5.36] 
0.77 
 
     CMV only   
1.89 [0.82, 4.37] 
0.14 
 
 
° Test result from Wald (overall) test without estimates 
§  
Risk factors which may be observed multiple times post-SOT over time until death and/or graft loss. 
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Figures 
 
Figure 1: Cumulative incidences of first CDI episodes according to transplant  
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